Business Segments (Tables)
|
12 Months Ended |
Mar. 31, 2026 |
| Segment Reporting [Abstract] |
|
| Schedule of Information about our Operating and Reportable Segments |
The tables below summarize information about our operating and reportable segments.
| | | | | | | | | | | | | | | | | | | | | | Year Ended March 31, 2026 | | (In thousands) | North American OTC Healthcare | | International OTC Healthcare | | | | Consolidated | | Total segment revenues* | $ | 913,576 | | | $ | 175,129 | | | | | $ | 1,088,705 | | | Cost of sales | 412,699 | | | 80,428 | | | | | 493,127 | | | Gross profit | 500,877 | | | 94,701 | | | | | 595,578 | | | Advertising and marketing | 120,847 | | | 27,935 | | | | | 148,782 | | | Contribution margin | $ | 380,030 | | | $ | 66,766 | | | | | 446,796 | | | Other operating expenses | | | | | | | 137,387 | | | Operating income | | | | | | | $ | 309,409 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
*Intersegment revenues of $3.8 million were eliminated from the North American OTC Healthcare segment.
| | | | | | | | | | | | | | | | | | | | | | Year Ended March 31, 2025 | | (In thousands) | North American OTC Healthcare | | International OTC Healthcare | | | | Consolidated | | Total segment revenues* | $ | 960,010 | | | $ | 177,752 | | | | | $ | 1,137,762 | | | Cost of sales | 428,871 | | | 74,428 | | | | | 503,299 | | | Gross profit | 531,139 | | | 103,324 | | | | | 634,463 | | | Advertising and marketing | 129,431 | | | 26,292 | | | | | 155,723 | | | Contribution margin | $ | 401,708 | | | $ | 77,032 | | | | | 478,740 | | | Other operating expenses** | | | | | | | 141,965 | | | Operating income | | | | | | | $ | 336,775 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
* Intersegment revenues of $3.9 million were eliminated from the North American OTC Healthcare segment. **Other operating expenses for the year ended March 31, 2025 includes a tradename impairment charge of $12.5 million
| | | | | | | | | | | | | | | | | | | | | | Year Ended March 31, 2024 | | (In thousands) | North American OTC Healthcare | | International OTC Healthcare | | | | Consolidated | | Total segment revenues* | $ | 958,260 | | | $ | 167,097 | | | | | $ | 1,125,357 | | | Cost of sales | 429,361 | | | 71,548 | | | | | 500,909 | | | Gross profit | 528,899 | | | 95,549 | | | | | 624,448 | | | Advertising and marketing | 131,494 | | | 21,821 | | | | | 153,315 | | | Contribution margin | $ | 397,405 | | | $ | 73,728 | | | | | 471,133 | | | Other operating expenses | | | | | | | 128,704 | | | Operating loss | | | | | | | $ | 342,429 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
*Intersegment revenues of $3.7 million were eliminated from the North American OTC Healthcare segment.
|
| Schedule of Information about our Revenues from Similar Product Groups |
The tables below summarize information about our segment revenues from similar product groups.
| | | | | | | | | | | | | | | | | | | | | Year Ended March 31, 2026 | | (In thousands) | North American OTC Healthcare | | International OTC Healthcare | | | | Consolidated | | Analgesics | $ | 108,300 | | | $ | 5,636 | | | | | $ | 113,936 | | | Cough & Cold | 76,878 | | | 25,031 | | | | | 101,909 | | | Women's Health | 205,053 | | | 22,712 | | | | | 227,765 | | | Gastrointestinal | 179,300 | | | 80,488 | | | | | 259,788 | | | Eye & Ear Care | 126,132 | | | 16,807 | | | | | 142,939 | | | Dermatologicals | 116,618 | | | 9,313 | | | | | 125,931 | | | Oral Care | 86,958 | | | 14,093 | | | | | 101,051 | | | Other OTC | 14,337 | | | 1,049 | | | | | 15,386 | | | | | | | | | | | Total segment revenues | $ | 913,576 | | | $ | 175,129 | | | | | $ | 1,088,705 | |
| | | | | | | | | | | | | | | | | | | | | Year Ended March 31, 2025 | | (In thousands) | North American OTC Healthcare | | International OTC Healthcare | | | | Consolidated | | Analgesics | $ | 112,173 | | | $ | 5,524 | | | | | $ | 117,697 | | | Cough & Cold | 82,533 | | | 23,681 | | | | | 106,214 | | | Women's Health | 216,335 | | | 20,496 | | | | | 236,831 | | | Gastrointestinal | 174,891 | | | 81,052 | | | | | 255,943 | | | Eye & Ear Care | 158,858 | | | 24,464 | | | | | 183,322 | | | Dermatologicals | 120,770 | | | 8,177 | | | | | 128,947 | | | Oral Care | 81,868 | | | 13,162 | | | | | 95,030 | | | Other OTC | 12,582 | | | 1,196 | | | | | 13,778 | | | | | | | | | | | Total segment revenues | $ | 960,010 | | | $ | 177,752 | | | | | $ | 1,137,762 | |
| | | | | | | | | | | | | | | | | | | | | Year Ended March 31, 2024 | | (In thousands) | North American OTC Healthcare | | International OTC Healthcare | | | | Consolidated | | Analgesics | $ | 111,996 | | | $ | 5,455 | | | | | $ | 117,451 | | | Cough & Cold | 93,575 | | | 25,445 | | | | | 119,020 | | | Women's Health | 217,103 | | | 23,318 | | | | | 240,421 | | | Gastrointestinal | 160,889 | | | 70,721 | | | | | 231,610 | | | Eye & Ear Care | 156,553 | | | 22,870 | | | | | 179,423 | | | Dermatologicals | 123,288 | | | 5,814 | | | | | 129,102 | | | Oral Care | 83,212 | | | 13,093 | | | | | 96,305 | | | Other OTC | 11,644 | | | 381 | | | | | 12,025 | | | | | | | | | | | Total segment revenues | $ | 958,260 | | | $ | 167,097 | | | | | $ | 1,125,357 | |
|
| Schedule of Segment Revenue by Geographic Area |
Our total segment revenues by geographic area are as follows: | | | | | | | | | | | | | | | | | | | Year Ended March 31, | | 2026 | | 2025 | | 2024 | | United States | $ | 850,414 | | | $ | 897,540 | | | $ | 886,470 | | | Rest of world | 238,291 | | | 240,222 | | | 238,887 | | | Total | $ | 1,088,705 | | | $ | 1,137,762 | | | $ | 1,125,357 | |
|
| Schedule of Allocation of Long-Term Assets to Segments |
Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: | | | | | | | | | | | | | | | | | | | |
March 31, 2026 (In thousands) | North American OTC Healthcare | | International OTC Healthcare | | | | Consolidated | | Goodwill | $ | 550,987 | | | $ | 30,122 | | | | | $ | 581,109 | | | | | | | | | | | Intangible assets | | | | | | | | | Indefinite-lived | 2,068,752 | | | 74,923 | | | | | 2,143,675 | | | Finite-lived | 138,903 | | | 17,027 | | | | | 155,930 | | | Intangible assets, net | 2,207,655 | | | 91,950 | | | | | 2,299,605 | | | Total | $ | 2,758,642 | | | $ | 122,072 | | | | | $ | 2,880,714 | |
| | | | | | | | | | | | | | | | | | | |
March 31, 2025 (In thousands) | North American OTC Healthcare | | International OTC Healthcare | | | | Consolidated | | Goodwill | $ | 498,936 | | | $ | 28,489 | | | | | $ | 527,425 | | | | | | | | | | | Intangible assets | | | | | | | | | Indefinite-lived | 2,068,752 | | | 68,234 | | | | | 2,136,986 | | | Finite-lived | 141,234 | | | 17,130 | | | | | 158,364 | | | Intangible assets, net | 2,209,986 | | | 85,364 | | | | | 2,295,350 | | | Total | $ | 2,708,922 | | | $ | 113,853 | | | | | $ | 2,822,775 | |
|
| Schedule of Goodwill and Intangible Assets by Geographic Areas |
Our goodwill and intangible assets by geographic area are as follows: | | | | | | | | | | | | | Year Ended March 31, | | 2026 | | 2025 | | United States | $ | 2,706,591 | | | $ | 2,708,922 | | | Rest of world | 174,123 | | | 113,853 | | | Total | $ | 2,880,714 | | | $ | 2,822,775 | |
|